Equillium reports first quarter 2024 financial results and provides recent clinical highlights

La jolla, calif.--(business wire)---- $eq--equillium inc. (nasdaq: eq), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced financial results for the first quarter 2024 and highlights in clinical development. “with multiple milestones expected in 2024, we are happy to have reported our first milestone of positive topline data from the phase 1b equalise study in lupus.
EQ Ratings Summary
EQ Quant Ranking